Daniel A. Ermann

Daniel A. Ermann

Auto-generated profile, based on publicly available information

Daniel A. Ermann

University of Utah

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
VVVictoria A. Vardell
Victoria A. Vardell
DEDaniel A. Ermann
Daniel A. Ermann
STSrinivas Tantravahi
Srinivas Tantravahi
BHBenjamin Haaland
Benjamin Haaland
BMBrian McClune
Brian McClune
DSDouglas Weston Sborov
Douglas Weston Sborov

19 January 2024 in American Journal of Hematology
Verified
Journal Article
Closed access
VVVictoria A. Vardell
Victoria A. Vardell
DEDaniel A. Ermann
Daniel A. Ermann
LFLindsey Fitzgerald
Lindsey Fitzgerald
HSHarsh Shah
Harsh Shah
BHBoyu Hu
Boyu Hu
DSDeborah M. Stephens
Deborah M. Stephens

20 April 2023 in American Journal of Hematology
Verified
Journal Article
Closed access
VVVictoria A. Vardell
Victoria A. Vardell
DEDaniel A. Ermann
Daniel A. Ermann
LFLindsey A. Fitzgerald
Lindsey A. Fitzgerald
HSHarsh R. Shah
Harsh R. Shah
BHBoyu Hu
Boyu Hu
DSDeborah M. Stephens
Deborah M. Stephens

10 October 2023 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
DEDaniel A. Ermann
Daniel A. Ermann
VVVictoria A. Vardell
Victoria A. Vardell
HSHarsh Shah
Harsh Shah
LFLindsey Fitzgerald
Lindsey Fitzgerald
RTRanda Tao
Randa Tao
BHBoyu Hu
Boyu Hu

15 June 2022 in eJHaem
Verified
Journal Article
Open access
AMAjay Major
Ajay Major
ECEdward R. Scheffer Cliff
Edward R. Scheffer Cliff
DEDaniel A. Ermann
Daniel A. Ermann
UDUrshila Durani
Urshila Durani
DRDavid A. Russler‐Germain
David A. Russler‐Germain
In the POLARIX trial, pola-R-CHP demonstrated improved progression-free survival (PFS) compared to R-CHOP in untreated intermediate- to high-risk DLBCL. We surveyed practicing clinicians regarding their interpretation of POLARIX, including impressions of efficacy, safety, and cost. Of 174 respondents, most from academic centers (82%) in the United States (57%), 70% stated they would not replace R-CHOP with pola-R-CHP due to insufficient PFS difference, lack of overall survival benefit, and excessive cost. Respondents not recommending pola-R-CHP expressed concerns about financial implications for both society and patients. We observed considerable heterogeneity in both study interpretation and plans for real-world implementation of pola-R-CHP.

5 November 2021 in Blood
Verified
Journal Article
Open access
VVVictoria A. Vardell
Victoria A. Vardell
DEDaniel A. Ermann
Daniel A. Ermann
STSrinivas Tantravahi
Srinivas Tantravahi
BMBrian McClune
Brian McClune
MSMary Nicole Steinbach
Mary Nicole Steinbach
DSDouglas Weston Sborov
Douglas Weston Sborov
Background Treatment at academic cancer centers (ACs) has been associated with improved outcomes across hematologic malignancies, including acute myeloid leukemia and non-Hodgkin lymphoma. ACs offer the benefit of high treatment volume in addition to enrollment in clinical trials, involvement in post-graduate education, and expanded access to diagnostic and treatment related services. Though studies on multiple myeloma (MM) have demonstrated a survival benefit with treatment at both high-volume centers and at NCCN designated cancer centers, this is the largest study to date examining the benefit of academic centers. Methods The National Cancer Database was utilized to obtain data on patients diagnosed with MM between 2004-2017 for which data on treatment facility type was available. Using the Commission on Cancer facility categories, patients treated at ACs were compared to those treated at non-academic centers (NACs), including small and large volume community cancer centers. Demographic and treatment characteristics were compared between centers, with median overall survival (OS) assessed by Kaplan Meier. Cox regression analysis was used to asses the HR for OS by facility type, and adjusted on multivariate analysis for age, sex, race, insurance, time to treatment, and use of autologous transplant. Results Of the 179,769 MM patients available, 42.4% were treated at ACs (p<0.05). Patients treated at ACs were younger than those treated at NACs (mean age 64.7 years vs. 69.2 years, p 75 years of age were more often treated at NACs (35.6% vs. 20.3%, p<0.05). ACs were more likely to treat Black and other minority patients, with Black patients representing 23.5% vs. 18%, and other minorities 5.6% vs. 3.6% of patients treated at ACs vs. NACs, respectively; all p<0.05. Academic centers were more likely to treat uninsured patients (6.3% vs. 4.1%), patients on Medicaid (7.9% vs. 5.5%) as well as privately insured patients (41.5% vs. 29.6%),( all p<0.05). The majority of Medicare patients were treated at NACs (60.8%), p<0.05. The time from diagnosis to treatment was longer at ACs, at 32.4 vs. 26.5 days (p<0.05), and patients were more likely to receive autologous stem cell transplant as first line treatment at ACs (6.3% vs 2.2%, p<0.05). While clinical trial data is limited in the NCDB, the majority of the 495 patients treated under a clinical trial were treated at ACs (393 vs 102, or 0.5% vs 0.1% of patients treated at ACs vs NACs, p<0.05). Median OS at ACs was significantly longer than at NACs, with median OS of 67.8 months (95% CI 66.89-68.79 months) compared to 38.6 months (95% CI 38.15-39.13 months) at NACs, p<0.05. One year OS was 75% vs 61%, 5-year OS 48% vs 33%, and 10-year OS of 22% vs 12% at ACs vs NACs, respectively; p<0.05. When adjusted for age, gender, race, insurance, time to treatment, and use of autologous transplant on Cox Regression analysis, the improvement in OS remained. Patients treated at AC had hazard ratio of 0.77 for all-cause mortality (95% CI 0.756-0.784) when referenced to NACs on multivariate analysis (p<0.05). Conclusion Patients with MM had significantly improved survival when treated at academic centers compared to all other facility types. The improvement in OS remained when controlled for available treatment and demographic features. Multiple factors, including specialized care, trial enrollment, and early access to autologous stem cell transplant may contribute to these improvements. Further investigations into the factors contributing to such disparities are required to standardize care and improve overall outcomes.